Previous 10 | Next 10 |
2024-01-29 02:13:56 ET More on Dare Bioscience Daré Bioscience to eliminate CFO and CCO roles to rein in costs Organon says Xaciato now available nationwide Seeking Alpha’s Quant Rating on Dare Bioscience Historical earnings data for Dare Biosc...
2024-01-26 16:50:49 ET More on Dare Bioscience Daré Bioscience, Inc. (DARE) Q3 2023 Earnings Call Transcript Organon says Xaciato now available nationwide Dare Bioscience secures $12M in royalty-backed investment structure Seeking Alpha’s Quant Ra...
SAN DIEGO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced changes in company management which includes the retirement of Chief Financial Officer, Lisa Walters-Hoffert, and the resignation of Chief Comme...
SAN DIEGO, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it has received a grant from the Bill & Melinda Gates Foundation (the foundation) of $750,000 to fund activities related to bacteria-based live...
2024-01-10 10:04:45 ET More on Dare Bioscience, Organon, etc. Organon & Co (OGN) J.P. Morgan 42nd Annual Healthcare Conference (Transcript) Organon: What I'm Looking For In This 8% Yield In 2024 High Risk, High Reward: Why 8.5%-Yielding Organon Could Be Up To 90%...
SAN DIEGO, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it has achieved technological proof of concept for DARE-LARC1 and the underlying innovative drug delivery platform designed to store and pr...
2023-12-26 08:36:16 ET More on Dare Bioscience Daré Bioscience, Inc. (DARE) Q3 2023 Earnings Call Transcript Dare Bioscience Q3 2023 Earnings Preview Daré Bioscience's stock rises ~15% on $1.8M milestone from Organon for Xaciato Seeking Alpha’...
SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it has entered into a royalty-backed financing agreement that provides Daré with $5 million at closing and up to an additional $7 million thro...
SAN DIEGO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced positive topline results from the Phase 1 study evaluating the pharmacokinetics (PK), safety, and exploratory efficacy of DARE-PDM1. DARE-PDM1 i...
DARE-PTB1 is being developed as a treatment to reduce the risk of preterm birth, for which there are no FDA-approved treatment options Up to approximately $2 million in grant funding to support DARE-PTB1 Phase 1 human clinical study SAN DIEGO, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Dar...
News, Short Squeeze, Breakout and More Instantly...
Dare Bioscience Inc. Company Name:
DARE Stock Symbol:
NASDAQ Market:
Shares of James Hardie Industries plc (NYSE:JHX) fell sharply during Tuesday's session after the company reported worse-than-expected quarterl...
Bayer AG (OTC:BAYRY) (OTC:BAYZF) will present detailed results from the Phase 3 studies OASIS 1 and 2, showing that the investi...
Development Program Highlights and Anticipated 2024 Milestones Ovaprene® hormone-free monthly intravaginal contraceptive candidate pivotal Phase 3 contraceptive efficacy study recruiting across the United States Sildenafil Cream, 3.6% topical formulation of sildenafil b...